Edition:
India

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

11.30USD
19 Jul 2018
Change (% chg)

$-5.16 (-31.35%)
Prev Close
$16.46
Open
$9.16
Day's High
$12.17
Day's Low
$8.76
Volume
272,676
Avg. Vol
48,707
52-wk High
$23.67
52-wk Low
$8.76

Chart for

About

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $429.84
Shares Outstanding(Mil.): 22.71
Dividend: --
Yield (%): --

Financials

Mersana's cancer drug trial put on hold by FDA; shares halted

Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient's death was possibly linked to the treatment.

19 Jul 2018

Mersana Therapeutics cancer drug trial on partial hold by FDA

July 19 Mersana Therapeutics said on Thursday its early-stage trial for its cancer drug has been put on partial hold by the U.S. health regulator after a patient's death was possibly related to the treatment.

19 Jul 2018

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

28 Mar 2018

BRIEF-Mersana Appoints David Spellman As Chief Financial Officer

* MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER

12 Mar 2018

Earnings vs. Estimates